Platelet size: measurement, physiology and vascular disease.
P. Bath,
R. Butterworth
|
9 |
1996 |
9
1996
|
Multi-centre investigation on reference ranges for ROTEM thromboelastometry
7 auth.
T. Lang,
A. Bauters,
S. Braun,
B. Pötzsch,
K. von Pape,
H. Kolde,
...
M. Lakner
|
8 |
2005 |
8
2005
|
Venous thromboembolism and cancer.
H. Rahr,
J. Sørensen
|
8 |
1992 |
8
1992
|
The platelet glycoprotein Ib-IX complex.
Jos A. L pez
|
8 |
1994 |
8
1994
|
Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII.
M. Hoffman,
D. M. M. rd,
H. Roberts
|
8 |
1998 |
8
1998
|
Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran
J. Stangier,
M. Feuring
|
8 |
2012 |
8
2012
|
Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study
10 auth.
R. Alikhan,
A. Cohen,
S. Combe,
M. Samama,
L. Desjardins,
A. Eldor,
...
C. Janbon,
A. Leizorovicz,
C. Olsson,
A. Turpie
|
7 |
2003 |
7
2003
|
Plasminogen: a structural review.
C. P. Ponting,
Julian M. Marshall,
Stewart A. Cederholm-Williams
|
7 |
1992 |
7
1992
|
Antithrombin: a new look at the actions of a serine protease inhibitor
Juergen Roemisch,
Elaine Gray,
Johannes N. Hoffmann,
C. J. Wiedermann
|
7 |
2002 |
7
2002
|
Clinical experience with recombinant factor VIIa.
J. Lusher,
J. Ingerslev,
H. Roberts,
U. Hedner
|
7 |
1998 |
7
1998
|
The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects
Halbmayer Wm,
A. Haushofer,
Renate Schön,
M. Fischer
|
7 |
1994 |
7
1994
|
Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis.
9 auth.
P. Harrison,
M. Robinson,
I. Mackie,
J. Joseph,
S. Mcdonald,
R. Liesner,
...
G. Savidge,
J. Pasi,
S. Machin
|
7 |
1999 |
7
1999
|
The effect of recombinant factor VIIa (NovoSeven™) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0
E. Erhardtsen,
P. Nony,
M. Dechavanne,
P. Ffrench,
J. Boissel,
U. Hedner
|
7 |
1998 |
7
1998
|
Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects
B. Sørensen,
Peter Johansen,
G. L. Nielsen,
J. C. Sørensen,
J. Ingerslev
|
7 |
2003 |
7
2003
|
Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven®) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery
10 auth.
M. Al Douri,
T. Shafi,
D. A. al Khudairi,
E. Al Bokhari,
L. Black,
N. Akinwale,
...
Osman Musa,
A. A. Homaidhi,
Al M. Fagih,
Borum R. Andreasen
|
7 |
2000 |
7
2000
|
Stability of coagulation proteins in frozen plasma
B. Woodhams,
O. Girardot,
B. Mj,
G. Colesse,
Y. Gourmelin
|
7 |
2001 |
7
2001
|
